Healthcare - Biotechnology - NASDAQ - US
$ 2.27
-7.72 %
$ 476 M
Market Cap
-1.46
P/E
BALANCE SHEET
643 M
ASSETS
131 M
LIABILITIES
512 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Allogene Therapeutics, Inc.
| Current Assets | 459 M |
| Cash & Short-Term Investments | 449 M |
| Receivables | 0 |
| Other Current Assets | 10.4 M |
| Non-Current Assets | 184 M |
| Long-Term Investments | 3.64 M |
| PP&E | 163 M |
| Other Non-Current Assets | 16.9 M |
| Current Liabilities | 37.1 M |
| Accounts Payable | 5.9 M |
| Short-Term Debt | 6.78 M |
| Other Current Liabilities | 24.4 M |
| Non-Current Liabilities | 93.5 M |
| Long-Term Debt | 88.3 M |
| Other Non-Current Liabilities | 5.18 M |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Cash & Cash Equivalents | 83.2 | 576.5 | 809.5 | 1 032.1 | 588.9 | 721.4 | 0 |
| Short Term Investments | 365.5 | 455.4 | 284.0 | 644.6 | 355.4 | 367.0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 2.4 | 3.1 | 0 |
| Inventory | 0 | (62.5) | (20.0) | (207.0) | (60.7) | (262.0) | 0 |
| Other Current Assets | 10.4 | 11.5 | 8.0 | 10.6 | 11.6 | 5.5 | 0 |
| Total Current Assets | 459.1 | 528.8 | 809.5 | 845.1 | 544.6 | 468.0 | 0 |
| PP&E | 163.2 | 196.4 | 181.0 | 160.1 | 100.9 | 41.6 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0.2 | 0.8 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 3.6 | 59.2 | 370.2 | 207.9 | 63.2 | 262.0 | 0 |
| Other Long Term Assets | 16.9 | 32.7 | (322.1) | 14.6 | 8.9 | 1.5 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 642.8 | 817.1 | 1 038.6 | 1 227.8 | 717.8 | 773.9 | 0 |
| LIABILITIES | |||||||
| Accounts Payable | 5.9 | 13.9 | 10.3 | 10.4 | 9.2 | 12.3 | 0 |
| Short Term Debt | 6.8 | 6.0 | 3.2 | 3.0 | 1.7 | 0 | 0 |
| Other Current Liabilities | 24.3 | 33.8 | 34.7 | 42.0 | 22.1 | 17.1 | 2 K |
| Total Current Liabilities | 37.1 | 54.5 | 48.2 | 94.3 | 33.1 | 29.5 | 2 K |
| Long Term Debt | 88.3 | 95.1 | 69.9 | 50.8 | 51.3 | 34.5 | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 5.2 | 5.8 | 4.1 | 3.1 | 4.4 | 6.8 | 0 |
| Total Liabilities | 130.6 | 151.2 | 122.2 | 148.2 | 88.8 | 70.7 | 2 K |
| EQUITY | |||||||
| Common Stock | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 26 K |
| Retained Earnings | (1 562.2) | (1 236.0) | (903.3) | (646.3) | (396.1) | (211.5) | 23 K |
| Other Accumulative Comprehensive Income/Loss | (1.0) | (9.9) | (2.6) | 0.3 | 1.1 | 0.3 | 5 K |
| Total Equity | 512.2 | 665.9 | 916.4 | 1 079.6 | 629.0 | 703.2 | 2 K |
| Total Liabilities and Equity | 642.8 | 817.1 | 1 038.6 | 1 227.8 | 717.8 | 773.9 | 0 |
| SHARES OUTSTANDING | |||||||
| Common Shares Outstanding | 156.9 | 143.1 | 135.8 | 120.4 | 101.1 | 28.9 | 117.9 |